INTRODUCTION
Protein kinases are enzymes that transfer the γ-phosphate group from ATP to a serine, threonine, or tyrosine residue in specific substrate proteins. These phosphorylation events modulate the activity of a vast number of proteins, including ion channels, transcription factors, proteases, and other kinases. It is estimated that one-third of the proteins in a typical mammalian cell are phosphorylated and approximately 2% of the genes in a typical eukaryotic cell are predicted to code for proteins that contain protein kinase domains (21) . Protein kinases function primarily as components of signaling pathways in which signals perceived at the surface of a cell are transduced through the cell by a series of phosphorylation events that ultimately bring about a cellular response, such as a change in the rate of gene transcription or the modulation of ion channel activity.
Protein kinases are classified into two major subfamilies: serine/threonine kinases and the protein tyrosine kinases. Protein tyrosine kinases can be further subdivided into receptor tyrosine kinases, of which the epidermal growth factor receptor is an example, and cytoplasmic tyrosine kinases, which include the src family of protein kinases. Both subfamilies of protein kinases play critical roles in a variety of cellular functions including cell growth, development, differentiation, membrane transport, and cell death (17, 23) . Abnormalities in signaling pathways can lead to various pathological conditions including many forms of cancer. For this reason, protein kinases are important targets for both basic research and drug development.
Drug development begins with the identification of molecular targets that play a central role in a particular disease state. The sequencing of the human genome (24) will undoubtedly benefit the drug discovery process by providing a plethora of new tractable or "druggable" molecular targets (26) . Prominent classes of molecular targets under investigation include G-protein coupled receptors (GPCRs), proteases, ion channels, nuclear receptors, as well as protein kinases. Protein kinases are attractive targets because of their prominent roles in many pathological states. This is especially true in the area of cancer therapeutics, where several compounds currently in clinical trials have been identified as potent protein kinase inhibitors. In fact, the FDA recently approved STI-571 (Gleevec™) for the treatment of chronic myeloid leukemia (CML). STI-571 is a small molecule inhibitor of the Bcr-Abl tyrosine kinase, a fusion protein generated by a reciprocal chromosomal translocation (9;22) that results in a shortened chromosome 22, known as the Philadelphia chromosome, which is present in virtually all CML patients (1, 6, 7) . The resultant fusion protein has higher than normal tyrosine kinase activity and functions as a leukemic oncogene in several animal models (5, 15, 18) . STI-571 acts as a competitive inhibitor of ATP binding and inhibits Abl kinase activity in the submicromolar range. In addition to Abl tyrosine kinase, STI-571 is also a potent inhibitor of the receptor for cKit (a stem cell factor) and the platelet-derived growth factor (PDGF) receptor. Thus, the pharmacological profile of STI-571 makes it a potential therapeutic for several proliferative disorders (1) . Other small molecule kinase inhibitors in clinical trials at this time include ZD1839, OSI-774 (EGF receptor inhibitors), PTK-787 (VEGF receptor inhibitor), flavopiridol (cyclin-dependent kinase inhibitor), and UCN-01 (protein kinase c and cyclin-dependent kinase inhibitor) (13, 16, 19, 25, 27) .
Screening drug candidates for their ability to modulate the activity of a specific protein kinase, or studying protein kinases in general, requires an assay that measures the activity of the kinase of interest. Numerous assay technologies are available; some are best suited for use with purified protein kinases, while others allow the researcher to measure the activity of a particular kinase in a crude tissue or cell extract. The ideal assay technology would be equally effective with both purified kinases and crude extracts. Another consideration for kinase assay technology is throughput. The throughput needs of individual researchers vary greatly, and a technology that allows a researcher to conveniently assay either a few samples at a time or thousands in a large screen is desirable. Thus, the ideal assay system is fast and easy to perform, provides a true estimate of enzyme activity under optimal kinetic conditions, and is amenable to the throughput that high-throughput screening users require. A protein kinase assay system based on the capture of biotinylated peptide substrates has been developed to meet these criteria.
HIGH-DENSITY STREPTAVIDIN-COATED MEMBRANES FOR MEASURING PROTEIN KINASE ACTIVITY
The most commonly used kinase assay method to quantitate peptide substrate phosphorylation is the P81 phosphocellulose filter assay (22) . This method relies on the capture of peptide substrate by phosphocellulose via electrostatic interactions between the positively charged substrate and the negatively charged P81 filter. Although P81 phosphocellulose is widely used, it has several drawbacks. First, the positively charged radiolabeled substrate is bound to the P81 filter by weak electrostatic forces, which can lead to the loss of labeled substrate during the washing procedure. Mild washing conditions can reduce peptide loss, but higher background counts often result, leading to poor signal-to-noise ratios and reduced sensitivity. Secondly, most enzyme preparations contain numerous kinases that will phosphorylate endogenous positively charged proteins, which are likely to bind to the P81 filter. Additionally, [γ-32 P]ATP preparations contain radiolabeled contaminants that possess a positive charge at low pH. The binding of these compounds results in higher backgrounds and lower signal-to-noise ratios (3). Finally, peptide substrates of equal positive charge often exhibit wide variability in binding to phosphocellulose filters (22) . Peptide substrates that do not contain at least two positively charged amino acids, such as arginine or lysine, will not efficiently bind to P81 filters (22) . The addition of these amino acids may alter the specificity of these substrates, making them substrates for other kinases.
Streptavidin-coated membranes used in conjunction with biotinylated protein kinase peptide substrates (SignaTECT ® Protein Kinase Assay Systems) overcome the drawbacks of P81 phosphocellulose assays. The streptavidin-coated membrane is made using a proprietary process that results in a high density of streptavidin (12) . The binding of biotin to streptavidin is rapid and very strong (K d =10 -15 M), and the association is unaffected by rigorous washing procedures, denaturing agents, extremes in pH, temperature, and salt concentrations. High signal-to-noise ratios are generated even with crude extracts, while the high substrate capacity allows for optimum reaction kinetics. The assay can be used to measure protein kinase activities using low-femtomole levels of purified enzyme or crude tissue/cell extracts. As outlined in Figure 1 , the assay steps and analysis of results using a biotincapture system to measure protein kinase activity are straightforward and require only common laboratory equipment. kinases in the sample. The bound, labeled substrate is quantitated by scintillation counting, phosphor imaging analysis, or using autoradiography in combination with a densitometer.
BROAD SPECTRUM DETECTION OF PROTEIN TYROSINE KINASE ACTIVITY
A protein tyrosine kinase (PTK) assay system based on biotin capture (SignaTECT PTK Assay System) combines a streptavidin-coated membrane with two biotinylated peptide substrates to overcome the difficulties commonly encountered when measuring PTK activity. The two novel biotinylated substrates (PTK Biotinylated Substrate #1-Biotin-EEEEAYGWLDF; PTK Biotinylated Substrate #2-Biotin-AEEEIYGELEA) each contain a single tyrosine phosphorylation site and are readily phosphorylated by a variety of PTKs. These peptide substrates have been optimized for broad specificity and ideal kinetic properties (i.e., low K m and high V max values). The ability to efficiently capture the biotinylated peptide substrates onto the streptavidin matrix independent of the amino acid sequence of the peptide allows multiple peptides to be compared. This advantage is illustrated in Figure 2, (12, 20) . This finding supports the observation that the acidic nature of most PTK peptide subCytokines: Receptors and Cell Signaling 109 The enzyme reaction was performed with substrate only (Substrate), enzyme only (PKA), or substrate plus enzyme. Reactions were terminated as described (3, 9) and sample aliquots (5 µL) were added to wells of a SAM 2 96 Biotin Capture Plate. The wells were washed using a vacuum manifold (4 washes of 2 M NaCl, 6 washes of 2 M NaCl/1% HPO 4 , 4 washes of water). The plates were dried and counted using a MicroBeta ® TriLux liquid scintillation counter (EG&G Wallac, Gaithersburg, MD, USA). Letters A-H represent replicate samples placed in random wells to examine well-to-well variations. Results are expressed in counts per minute (cpm). Avg. = average; S.D. = standard deviation; %CV = percent coefficient of variation. Table 1 . The inset is an enlargement of the 0-50 pmol portion of the graph.
strates results in poor capture onto phosphocellulose filters even if additional basic amino acids are added to improve capture efficiencies (4, 14, 22, 28) . Although there are a variety of peptide substrates commonly used to measure PTK enzyme activity (e.g., p34 cdc2 -derived peptide, gastrin [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and src-derived peptide), these peptides typically have K m values greater than 300 µM and often greater than 1 mM (Figure 3B; 8) . In contrast, titration of the abovementioned biotinylated peptide substrates demonstrates very low K m values (10-60 µM). In addition, the V max values observed with these optimized peptide substrates are 2-to 5-fold higher than values obtained with the p34 cdc2 -derived peptide, gastrin [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , and the src-derived peptide (12, 20) .
HIGH-THROUGHPUT APPLICATIONS
In addition to a perforated 10-× 15-cm sheet, the high-density streptavidin matrix is available in formats more conducive to high-throughput applications. These include the development of a single sheet format (7.6 × 10.9 cm) and the 96-well biotin capture plate.
To illustrate the performance of the 96-well biotin capture plate in a high-throughput situation, a protein kinase A (PKA) assay was performed (Table 1) . PKA activity was measured in the presence of enzyme alone, in the presence of substrate alone, and in the presence of both enzyme and substrate (10) . The radioactivity determined in the absence of the enzyme ("Substrate") or in the absence of the substrate ("PKA") represents <0.02% of input counts. The range of background counts was extremely low and the assay was carried out with maximum efficiency of time; the full washing procedure took only 5 minutes. It is also noteworthy that the coefficient of variation for enzyme activity did not exceed 8%, indicating highly reproducible results and consistency in the assay performance. When tested with biotin and biotinylated peptides, the binding capacity of the biotin-capture plate was linear between 1 and 500 pmol/well and binding was stoichiometric, as demonstrated in Figure 4 (11). This feature is critical for enzymes such as PTK whose substrates have high K m values.
µARCS TECHNOLOGY
Abbott Laboratories (Abbott Park, IL, USA) has expanded the capabilities of the biotin-capture membrane technology by developing a high-throughput assay based on gel permeation of arrayed compounds. Using the microarray compound screening (µARCS) technology, approximately 9000 compounds can be screened in a single assay (2) . Nanoliter quantities of test compounds are arrayed onto a polystyrene sheet that has the same footprint as a microtiter plate ( Figure 5 ). The compound sheet is dried and then overlaid onto an agarose gel containing the kinase of interest. After allowing the compounds to diffuse into the kinase gel, the polystyrene sheet is removed and the kinase gel is then layered onto a streptavidin-coated membrane cut to the same dimensions as the gel. The kinase reaction is initiated by overlaying a substrate gel containing the biotinylated peptide substrate and [ 33 P]ATP onto the kinase gel. The peptide substrate and [ 33 P]ATP diffuse through the kinase gel, and the biotinylated peptide is captured on the streptavidincoated membrane. The membrane is then washed to remove nonspecific radioactivity, and signal is detected using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). In the absence of inhibitor, the peptide substrate gets phosphorylated with [ 33 P], and the output from PhosphorImager analysis appears as a light background (reverse image). Dark spots on a light background suggest the presence of a kinase inhibitor in that region of the assay. This technology allows Abbott Laboratories to screen 50 000 to 100 000 compounds in a single day. The µARCS technology reduces both reagent consumption and costs compared to standard plate screening techniques and does not suffer from many of the drawbacks common to high-density plate screening, such as complex liquid-handling requirements, evaporation problems, plate edge effects, and extensive automation requirements (2).
SUMMARY
The study of kinases and their role in cellular regulation continues to expand as the human genome is sequenced and new kinases are identified as expression products of newly discovered genes. Reagents and assay systems that allow for sensitive, accurate, and high-throughput analysis of both purified kinases as well as crude extracts will enhance the characterization of these important cellular components and will speed the identification of appropriate therapeutic targets and the development of new and more effective treatments. 
